Figura Suplementaria 2 de la Co-mutación RAS/RAF y el Número de Copias ERBB2 Modulan la Heterogeneidad de HER2 y la Responsividad a la Terapia Dirigida a HER2 en Cáncer Colorrectal

Singh et al. (Mon,) estudiaron esta cuestión.

www.synapsesocial.com/papers/68e6f2a2b6db64358766d0ea — DOI: https://doi.org/10.1158/1078-0432.25603663

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 2 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
2. Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
3. Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
4. Supplementary Figure 1 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
5. Supplementary Figure 1 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024